ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization.
Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain’s field potential and electrical signals at the neuron-level across different brain regions can provide critical information in elucidating neural network function and the biological pathway behind neurological disease pathology.
However, in vivo electrophysiology is challenging due to the inherent complexity of the neural network. This not only includes data acquisition, but also consideration for the in vivo animal model, which is predominantly rodent in nature. The probes offered are designed to work without a headstage, reducing the physical burden on the animal heads without compensating in signal channels. Deep-array electrodes are also offered with a 90mm recording depth over 128 channels.
As a complement to the probes, data acquisition systems along with AI / cloud-based data analysis software are available to drive structural and functional analysis of neural circuits, electrophysiological biomarker discovery and drug screening. For those that are looking to start their initial foray into the neurosciences, beginner’s guides & trainings are offered to get their experiments up-and-running.
Under Aneuro, all in vivo electrophysiology alongside other neurological drug-development products including pre-formed fibrils (PFFs), Tau, and many other protein antigens associated with neurological diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, brain tumors and other neurological related diseases.